biotech sector

Rumor has it that if the S&P 500 finishes its first five trading days of the year with a gain, then the year in question will -- 80 percent of the time -- end with a gain as well. Last Thursday’s rally gave the S&P that five-day gain. However, since that day, the market has seen a...

The ongoing Ebola epidemic has refocused the world's attention on biotechs, as the ZMapp serum, from San Diego's Mapp Biopharmaceutical, helped treat two American infectees earlier this year. That's not the only thing the space has going for it, though. VC Investment Is...

With the death toll from West Africa’s Ebola outbreak reaching close to 1,000, serious interest is being taken into researching compounds that could both prevent outbreak and help those infected. Until recently, Ebola was a pretty rare disease, Dr. Jim Wilson told Benzinga, and the...

In last week’s Benzinga article on InterMune (NASDAQ: ITMN), some of the warning signs for the overall stock market were highlighted. Those warnings became more than just warnings last week, as the market took some significant hits. Last Thursday’s 300-plus drop on the Dow Jones...

One of the best performers in the incredible bull run for the market has been the biotech sector. Many of the stocks in the sector have doubled, tripled, quadrupled and, in the case of Biogen (NASDAQ: BIIB), decupled (ten times) in price. BIIB, which bottomed in Nov. 2008 ($37.21) and peaked...

Biotech stocks have been one of the hottest sectors of the market over the last several years and many exchange traded funds have benefitted greatly from their success. The two largest ETFs in this space are the iShares NASDAQ Biotechnology ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSE:...

Is Amarin's (NASDAQ: AMRN) Vascepa the victim of its own ineptitude, or the target of an effort by Big Pharma to keep it off the market? Those questions and others have been lobbed around lately by a variety of industry observers and investors, regarding Amarin's sole product, Vascepa – a...